See What HealthDay Can Do For You
Contact Us

Celecoxib Safe, Effective for Brucellosis-Associated Depression

Greater response to treatment in celecoxib versus placebo group at study end

FRIDAY, May 29, 2015 (HealthDay News) -- Celecoxib seems safe and effective for treatment of depression due to acute brucellosis, according to a study published online May 26 in the Journal of Clinical Pharmacy and Therapeutics.

Sara Jafari, M.D., from the Tehran University of Medical Sciences in Iran, and colleagues conducted a randomized trial involving 40 outpatients with depression due to brucellosis with a Hamilton Depression Rating Scale score (HDRS) <19. Participants were randomized to eight weeks of treatment with celecoxib or placebo as an adjunct to antibiotic therapy.

The researchers observed a significant effect for time × treatment interaction on the HDRS score in repeated-measures analysis (P < 0.001). At the study end there was a significantly greater response to treatment in the celecoxib versus placebo group (50 versus 0 percent; P < 0.001). There were no serious adverse events.

"Celecoxib is a safe and effective treatment for brucellosis-associated depression when compared with placebo," the authors write. "Celecoxib was associated with fast improvement in depressive symptoms, which makes this drug a potentially useful augmentative strategy in patients with brucellosis."

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.